Noveltreat vs Ozempic: Comparison Guide

Noveltreat vs Ozempic: Comparison Guide

If you are comparing Noveltreat and Ozempic, the first thing to know is that Noveltreat is an actual semaglutide brand in India, not a placeholder for future obesity drugs.

This guide compares the two products using the correct brand and formulation context so you can have a more useful conversation with your doctor. Consult your healthcare provider before starting any medication.

What is Ozempic?

Ozempic is Novo Nordisk's brand for semaglutide, a GLP-1 receptor agonist used in adults with type 2 diabetes and widely discussed because semaglutide can also support appetite reduction and weight change.

Ozempic is taken as a once-weekly injection.

What is Noveltreat?

Noveltreat is a Sun Pharma semaglutide injection brand in India. Sun Pharma's launch materials describe Noveltreat and Sematrinity as its semaglutide brands in the Indian market.

That means Noveltreat should be discussed as a real branded semaglutide option, not as a hypothetical dual-action or oral next-generation medicine.

What they have in common

Noveltreat and Ozempic share the same active ingredient: semaglutide.

That means both are discussed in relation to:

• improved glucose control in type 2 diabetes
• slower gastric emptying
• reduced appetite in many users
• weekly injection-based treatment plans

Key differences: Noveltreat vs Ozempic

1. Manufacturer

• Ozempic is made by Novo Nordisk.
• Noveltreat is associated with Sun Pharma in India.

2. Market context

Ozempic is the internationally established originator semaglutide brand. Noveltreat is part of the newer India-market semaglutide rollout from a domestic manufacturer.

3. Access and device workflow

Even with the same active ingredient, pen design, refill process, and local availability can differ between brands.

4. Evidence base

The best-known semaglutide trial evidence is tied to the broader originator evidence base. Clinicians still interpret Noveltreat through that semaglutide evidence while also checking local product details and approval context.

Side effects and safety

Because both are semaglutide-based, the expected side-effect profile is broadly similar. Common effects may include:

• nausea
• vomiting
• diarrhoea
• constipation
• abdominal discomfort
• lower appetite

Bottom line

Noveltreat and Ozempic are both semaglutide injection brands. The main difference is brand and market context—Sun Pharma's Noveltreat in India versus Novo Nordisk's Ozempic—not a present-versus-future drug comparison.

A clinician can help you compare dosing, device workflow, and access based on your prescription plan. Consult your healthcare provider before starting any medication.

Sources

• https://sunpharma.com/wp-content/uploads/2026/03/PR-for-Semaglutide.pdf
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• https://cdsco.gov.in/opencms/opencms/en/Home/
• https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• https://medlineplus.gov/druginfo/meds/a618008.html